Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Institut Pasteur › Francois Rougeon
FR

Francois Rougeon — 15 Patents

IPInstitut Pasteur: 15 patents #28 of 1,210Top 3%
CNCNRS: 7 patents #218 of 11,908Top 2%
Sèvres, FR: #6 of 158 inventorsTop 4%
Overall (All Time): #307,048 of 4,157,543Top 8%
15 Patents All Time
Francois Rougeon has been granted 15 US patents while listed as an inventor at Institut Pasteur. The first was granted in 1998 and the most recent in January 2019. Francois Rougeon ranks #307,048 of 4,157,543 US inventors in our database (top 7.4%). Patent records list Francois Rougeon in Sèvres, FR.

Patents per Year

Patents granted per year, 1998 to 2019Bar chart with a peak of 3 patents in 2008.peak 31998: 1 patents19981999: 1 patents2000: 1 patents20002003: 1 patents2004: 1 patents20042005: 1 patents2006: 1 patents20062008: 3 patents2009: 1 patents20092013: 1 patents2016: 1 patents20162018: 1 patents2019: 1 patents2019

Issued Patents All Time

Showing 1–15 of 15 patents

Patent #TitleCo-InventorsDate
10174105 Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications Pierre Lafaye, Jean-Pierre Bourgeois 2019-01-08
10155054 Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins Pierre Lafaye, Jean-Pierre Bourgeois 2018-12-18
9387260 VHH antibodies used as peptide vectors for delivering a substance of interest Pierre Lafaye, Jean-Pierre Bourgeois 2016-07-12
8460888 Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins Pierre Lafaye, Jean-Pierre Bourgeois 2013-06-11
7625713 Process for identifying a ligand that binds to the NEP binding site for the SMR1 pentapeptide Catherine Rougeot 2009-12-01
7429448 Therapeutic use of the SMR1 protein and active derivatives thereof Catherine Rougeot 2008-09-30
7423020 Treatment of mood disorders by administration of SMR1 Catherine Rougeot 2008-09-09
7387778 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders Tony Marcel, Catherine Rougeot 2008-06-17
7153833 Therapeutic uses of SMR1 peptides Catherine Rougeot 2006-12-26
6916607 PEPTIDES AND POLYPEPTIDES DERIVED FROM THE SUBMAXILLARY GLAND OF THE RAT CORRESPONDING POLYCLONAL AND MONOCLONAL ANTIBODIES CORRESPONDING HYBRIDOMAS AND USES OF THESE PRODUCTS FOR DIAGNOSIS FOR DETECTION OR THERAPEUTIC PURPOSES Isabelle Rosinski-Chupin, Diana Tronik, Nabil G. Seidah 2005-07-12
6818405 Therapeutic use of the SMR1 protein and active derivatives thereof Catherine Rougeot 2004-11-16
6589750 Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives Catherine Rougeot 2003-07-08
6025143 Antibodies directed against peptides derived from the SMR1 polypeptide Isabelle Rosinski-Chupin, Diana Tronik, Nabil G. Seidah 2000-02-15
5859189 Peptides and polypeptides derived from the submaxillary gland of the rat, corresponding polyclonal and monoclonal antibodies, corresponding hybridomas and uses of these products for diagnosis, for detection or therapeutic purposes Isabelle Rosinski-Chupin, Diana Tronik, Nabil G. Seidah 1999-01-12
5756323 Method for generating structural and functional diversity in a peptide sequence Sacha Kallenbach, Noelle Doyen 1998-05-26

Frequent Collaborators

Catherine Rougeot7 shared
Pierre Lafaye4 shared
Jean-Pierre Bourgeois4 shared
Diana Tronik3 shared
Isabelle Rosinski-Chupin3 shared
Nabil G. Seidah3 shared

Nearby-Ranked Inventors

Naoya Kasahara15
Aaron Larry Snyder15
Avishay Meron15
Stuart Hatfield15
Satoshi KUNIYASU15
Ashton Mason15
Theodore Yuchiang Cheng15
Richard Sharbaugh15
Rajen Bhatt15